Detalhe da pesquisa
1.
Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab.
Am J Hematol
; 92(11): 1156-1162, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28719025
2.
Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A second experience.
Am J Hematol
; 93(5): E123-E125, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29417621
3.
Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences.
Target Oncol
; 18(5): 727-734, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37728835
4.
Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy.
Leuk Lymphoma
; 59(10): 2287-2296, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29115892
5.
CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies.
Blood Cancer J
; 8(7): 63, 2018 06 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-29946110
6.
Immunotherapy for multiple myeloma: Current status and future directions.
Crit Rev Oncol Hematol
; 96(3): 399-412, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26153389
7.
Interobserver variability of mitotic index and utility of PHH3 for risk stratification in gastrointestinal stromal tumors.
Am J Clin Pathol
; 143(3): 385-92, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25696796
8.
Relationship of serum imatinib trough level and response in CML patients: long term follow-up.
Leuk Res
; 34(12): 1573-5, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-20688395